GB202005858D0 - H4 Antagonist compounds - Google Patents

H4 Antagonist compounds

Info

Publication number
GB202005858D0
GB202005858D0 GBGB2005858.2A GB202005858A GB202005858D0 GB 202005858 D0 GB202005858 D0 GB 202005858D0 GB 202005858 A GB202005858 A GB 202005858A GB 202005858 D0 GB202005858 D0 GB 202005858D0
Authority
GB
United Kingdom
Prior art keywords
antagonist compounds
antagonist
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005858.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70859977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB202005858(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB2005858.2A priority Critical patent/GB202005858D0/en
Publication of GB202005858D0 publication Critical patent/GB202005858D0/en
Priority to PCT/GB2021/050971 priority patent/WO2021214469A1/en
Priority to US17/920,583 priority patent/US20230167094A1/en
Priority to EP21722982.2A priority patent/EP4139300A1/en
Priority to JP2022564280A priority patent/JP7671307B2/ja
Priority to MX2022013340A priority patent/MX2022013340A/es
Priority to BR112022021395A priority patent/BR112022021395A2/pt
Priority to CN202180030226.4A priority patent/CN115916770B/zh
Priority to CA3180853A priority patent/CA3180853A1/en
Priority to KR1020227036308A priority patent/KR20230004512A/ko
Priority to AU2021260142A priority patent/AU2021260142A1/en
Priority to IL297469A priority patent/IL297469A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB2005858.2A 2020-04-22 2020-04-22 H4 Antagonist compounds Ceased GB202005858D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds
IL297469A IL297469A (en) 2020-04-22 2021-04-22 h4 antagonist compounds
AU2021260142A AU2021260142A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds
MX2022013340A MX2022013340A (es) 2020-04-22 2021-04-22 Compuestos antagonistas de h4.
US17/920,583 US20230167094A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds
EP21722982.2A EP4139300A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds
JP2022564280A JP7671307B2 (ja) 2020-04-22 2021-04-22 Ｈ４アンタゴニスト化合物
PCT/GB2021/050971 WO2021214469A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds
BR112022021395A BR112022021395A2 (pt) 2020-04-22 2021-04-22 Compostos antagonistas de h4
CN202180030226.4A CN115916770B (zh) 2020-04-22 2021-04-22 H4拮抗剂化合物
CA3180853A CA3180853A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds
KR1020227036308A KR20230004512A (ko) 2020-04-22 2021-04-22 H4 길항제 화합물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds

Publications (1)

Publication Number Publication Date
GB202005858D0 true GB202005858D0 (en) 2020-06-03

Family

ID=70859977

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005858.2A Ceased GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds

Country Status (12)

Country Link
US (1) US20230167094A1 (https=)
EP (1) EP4139300A1 (https=)
JP (1) JP7671307B2 (https=)
KR (1) KR20230004512A (https=)
CN (1) CN115916770B (https=)
AU (1) AU2021260142A1 (https=)
BR (1) BR112022021395A2 (https=)
CA (1) CA3180853A1 (https=)
GB (1) GB202005858D0 (https=)
IL (1) IL297469A (https=)
MX (1) MX2022013340A (https=)
WO (1) WO2021214469A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
GB201817047D0 (en) * 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Also Published As

Publication number Publication date
CN115916770A (zh) 2023-04-04
MX2022013340A (es) 2023-02-22
JP2023522405A (ja) 2023-05-30
KR20230004512A (ko) 2023-01-06
AU2021260142A1 (en) 2022-11-17
BR112022021395A2 (pt) 2022-12-13
WO2021214469A1 (en) 2021-10-28
EP4139300A1 (en) 2023-03-01
CN115916770B (zh) 2025-02-28
JP7671307B2 (ja) 2025-05-01
IL297469A (en) 2022-12-01
US20230167094A1 (en) 2023-06-01
CA3180853A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP4452937A4 (en) CONNECTIONS
IL300211B1 (en) Antagonist compounds
GB201817047D0 (en) H4 antagonist compounds
GB202019622D0 (en) Antagonist compounds
GB202013558D0 (en) GRP52 Modularor compounds
GB202001564D0 (en) Compounds
GB202005858D0 (en) H4 Antagonist compounds
GB202005877D0 (en) H4 antagonist compounds
GB202019667D0 (en) H4 antagonist comnpounds
GB202011811D0 (en) Compounds
GB202011812D0 (en) Compounds
GB201918392D0 (en) H4 Antagonist compounds
GB201901868D0 (en) H4 antagonist compounds
HK40094661A (en) H4 antagonist compounds
HK40084845A (en) H4 antagonist compounds
GB202019922D0 (en) Antagonist compounds
GB202011892D0 (en) Antagonist compounds
GB202006823D0 (en) Antagonist compounds
ES3063655T3 (en) Compounds
GB202201151D0 (en) Antagonist compounds
CA202363S (en) Barrier
GB202000906D0 (en) Antagonist
GB202117381D0 (en) Barrier
GB202010318D0 (en) Barrier
GB202014255D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)